Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Summary

This study will evaluate the safety and tolerability of IL-2 when given in combination with pembrolizumab to patients with advanced melanoma. Aldesleukin may stimulate white blood cells to melanoma cells. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving aldesleukin and pembrolizumab may kill more tumor cells. There are two parts to this study: * Phase Ib: To determine the safety and side effects of increasing doses of IL-2 in combination with pembrolizumab * Phase II: Once the maximum tolerated dose of IL-2 is determined, additional patients will be treated to determine if it is effective against the cancer.

Timeline

Start

2017-03-21

Primary completion

2018-10-18

Completion

2023-06-05

Outcome

Outcome not reported

Stopped: “Study Complete”

Publications

• Silk AW, Curti B, Bryan J, Saunders T, Shih W, Kane MP, Hannon P, Fountain C, Felcher J, Zloza A, Kaufman HL, Mehnert JM, McDermott DF. A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma. Front Oncol. 2023 Feb 9;13:1108341. doi: 10.3389/fonc.2023.1108341. eCollection 2023.

Drugs

Indications